Sirona Biochem Announces SGLT2 Inhibitor and Skin Lightening Patent Granted
Marketwired - Mon Jun 29, 7:01AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) is pleased to announce that its patent entitled "Family of aryl, heteroaryl, o-aryl and o-heteroaryl carbasugars" has been granted by the African Regional Intellectual Property Organization (composed of 19 African countries) and the patent office of South Africa. It is in the process of being granted by the European Patent Office and the patent office of Singapore. The process is proceeding without any known obstacles in the final regions. The patent is one of seven owned by Sirona's subsidiary, TFChem, and covers the SGLT2 Inhibitor as well as the skin lightening technology specific to TFC-849.
SBM.VN: 0.170 (+0.005)
Sirona Biochem Appoints Casper Bych to Its Board of Directors
Marketwired - Fri Jun 26, 7:30PM CDT
Sirona Biochem Corp. ("Sirona"
SBM.VN: 0.170 (+0.005)
Sirona Biochem CEO Update: Significant Interest From Top Cosmetic and Pharmaceutical Companies for Lead Compounds
Marketwired - Wed Jun 03, 7:01AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) today provided a business update.
SBM.VN: 0.170 (+0.005)
Sirona Biochem Discovers Unexpected Ancillary Effects of Its Anti-Aging Compound
Marketwired - Wed May 20, 7:01AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) is pleased to announce that its lead anti-aging compound also shows antioxidant properties in early preclinical studies.
SBM.VN: 0.170 (+0.005)
Sirona Biochem to Present at Industry's Premier Conference -- BIO International Convention 2015
Marketwired - Mon May 04, 7:01AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) announces that its Chief Business Development Officer, Attila Hajdu, will be presenting at BIO International, taking place June 15-18 at the Pennsylvania Convention Center, Philadelphia, PA.
SBM.VN: 0.170 (+0.005)
Sirona Biochem Announces Resignation of Board Director
Marketwired - Fri May 01, 8:00PM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) announced today the resignation of Michael Rogers from the board of directors. Mike served on the board since December 2010.
SBM.VN: 0.170 (+0.005)
Sirona Biochem to Present at BioNetwork East -- May 2015
Marketwired - Mon Apr 13, 7:02AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB), announces that its Chief Business Development Officer, Attila Hajdu, will be presenting at BioNetwork East on May 4th, 2015 at the Trump International Beach Resort in Miami Florida.
SBM.VN: 0.170 (+0.005)
Sirona Biochem Announces Positive Results With SBM-TFC-837 for Anti-Aging and Regenerative Medicine
Marketwired - Tue Mar 24, 7:02AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) is pleased to announce that its French partner, Biogalenys, observed positive effects of Sirona's glycoprotein SBM-TFC-837 on human fibroblasts in preliminary, in vitro, studies in response to the stressed condition of ultraviolet (UV) radiation.
SBM.VN: 0.170 (+0.005)
Sirona Biochem to Present at BIO Asia 2015 and Received Over $1.1 Million of Warrants Exercised
Marketwired - Thu Mar 12, 1:49PM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) announces that its Chief Business Development Officer, Attila Hajdu, will be presenting at BIO Asia, March 24-25, 2015 in Tokyo, Japan. The Company's CSO, Dr. Geraldine Deliencourt-Godefroy, will also be attending.
SBM.VN: 0.170 (+0.005)
Sirona Biochem Announces Successful Development of a Third Skin Lightener With Superior Safety and Efficacy
Marketwired - Wed Mar 11, 3:00AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) announces the successful development of a third innovative skin-lightening compound that has superior safety, with zero hydroquinone release and 8 times the efficacy of deoxyarbutin. This innovation was made possible through Sirona's platform technology of fluorination chemistry and through support of the European Union and the European Regional Development Fund (E.R.D.F.).
SBM.VN: 0.170 (+0.005)